entertainment -WSS

entertainment

author：entertainment 2025-10-04 04:00:26 - browse：2

A vial of Tofersen injection on the left of its box — The ALS drug tofersen is marketed as Qalsody in the U.S. Biogen

LONDON — Neurologists and patient advocates are up in arms over a policy decision by a U.K. health agency that they say will imperil access to an ALS treatment that’s available in the U.S. and on its way to approval in the European Union.

The medicine in question, Biogen’s tofersen, is designed to treat a rare genetic form of the neurodegenerative disease, accounting for some 2% of all ALS cases. And the issue is how the U.K.’s cost-effectiveness agency has said it would assess the costs and benefits of the therapy.

The agency, the National Institute for Health and Care Excellence, or NICE, has a special pathway for drugs for very rare diseases, which advocates and doctors argue is the route through which tofersen should be reviewed. But NICE has indicated it would review the drug through its standard process, saying it’s because ALS as a whole does not count as a “very rare” disease. That sets a higher bar to clear.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： UCB departs biotech trade group BIO

WSS

Rise in cancer among younger people worries and puzzles doctors

Susan Tousi leaves Illumina to head cancer liquid biopsy startup

Democrats decry new health bill for going easy on private equity

Truvian presents data for its desktop blood

The biotech scorecard for Q1: 17 stock

Search called off for baby washed away in Pennsylvania flash flood

focus

entertainment

explore

DIEP, the 'gold standard' of breast reconstruction, is under threat

The battle over 'scope creep' and who gets to be called 'doctor'

Virginia high school admissions case could be legal follow

New weight loss drugs work. But how can they best be used?

Jerome Adams on the need for new antivirals for Covid

Feng Zhang CRISPR delivery startup lays off quarter of staff

Continuity nursing helped my family in our darkest PICU moments

Dems pitch expanding Medicare power to negotiate drug prices

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Russian fighter jet damages US Reaper drone with flare over Syria: Officials

hotspot

The haunting brain science of long Covid

Dems pitch expanding Medicare power to negotiate drug prices

Bronny James, LeBron's son, suffers cardiac arrest during basketball practice at USC

Insitro, AI biotech unicorn, brings cash, new research to JPM 2024

U.K. sequencing study surfaces new findings about tumor DNA

AdventHealth escalates lawsuit against insurance vendor Multiplan

entertainment

knowledge

entertainment

hotspot